MX2014002736A - N-[4-(1h-pirazolo[3,4-b]pirazin-6-il)-fenil]-sulfonamidas y su uso como productos farmaceuticos. - Google Patents

N-[4-(1h-pirazolo[3,4-b]pirazin-6-il)-fenil]-sulfonamidas y su uso como productos farmaceuticos.

Info

Publication number
MX2014002736A
MX2014002736A MX2014002736A MX2014002736A MX2014002736A MX 2014002736 A MX2014002736 A MX 2014002736A MX 2014002736 A MX2014002736 A MX 2014002736A MX 2014002736 A MX2014002736 A MX 2014002736A MX 2014002736 A MX2014002736 A MX 2014002736A
Authority
MX
Mexico
Prior art keywords
sgk
formula
activity
pyrazin
pyrazolo
Prior art date
Application number
MX2014002736A
Other languages
English (en)
Other versions
MX342869B (es
Inventor
Marc Nazare
Nis Halland
Friedemann Schmidt
Tilo Weiss
Uwe Dietz
Armin Hofmeister
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2014002736A publication Critical patent/MX2014002736A/es
Publication of MX342869B publication Critical patent/MX342869B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a N-[4-(1H-pirazolo[3,4-b]pirazin -6-il)-fenil]-sulfonamidas de la fórmula I, (ver Fórmula) en donde Ar, R1, R2 y n tienen el significado que se indica en las reivindicaciones. Los compuestos de la fórmula I son valiosos compuestos farmacológicamente activos que modulan la actividad de una proteína quinasa, específicamente la actividad de la quinasa regulada por suero y glucocorticoides (SGK), en particular la isoforma 1 de la quinasa regulada por suero y glucocorticoides (SGK-1, SGK1) y son adecuados para el tratamiento de enfermedades en las que la actividad de SGK es inadecuada, por ejemplo trastornos degenerativos de las articulaciones o procesos inflamatorios tales como la artrosis o el reumatismo. La invención además se refiere a los procedimientos para la preparación de los compuestos de la fórmula I, su uso como productos farmacéuticos y las composiciones farmacéuticas que los comprenden.
MX2014002736A 2011-09-19 2012-09-18 N-[4-(1h-pirazolo[3,4-b]pirazin-6-il)-fenil]-sulfonamidas y su uso como productos farmaceuticos. MX342869B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306179.0A EP2570415B1 (en) 2011-09-19 2011-09-19 N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals
PCT/EP2012/068291 WO2013041502A1 (en) 2011-09-19 2012-09-18 N-[4-(1h-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals

Publications (2)

Publication Number Publication Date
MX2014002736A true MX2014002736A (es) 2014-05-01
MX342869B MX342869B (es) 2016-10-17

Family

ID=46875813

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002736A MX342869B (es) 2011-09-19 2012-09-18 N-[4-(1h-pirazolo[3,4-b]pirazin-6-il)-fenil]-sulfonamidas y su uso como productos farmaceuticos.

Country Status (17)

Country Link
US (1) US9174993B2 (es)
EP (2) EP2570415B1 (es)
AR (1) AR087907A1 (es)
BR (1) BR112014006207A2 (es)
CY (1) CY1117006T1 (es)
DK (1) DK2570415T3 (es)
EA (1) EA024295B1 (es)
ES (2) ES2552836T3 (es)
HR (1) HRP20151183T1 (es)
HU (1) HUE026072T2 (es)
MX (1) MX342869B (es)
MY (1) MY179987A (es)
PL (1) PL2570415T3 (es)
PT (1) PT2570415E (es)
SI (1) SI2570415T1 (es)
TW (1) TWI577679B (es)
WO (1) WO2013041502A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018106459A1 (en) 2016-12-07 2018-06-14 New Era Pharma, Inc. Compounds and pharmaceutical compositions for modulating sgk activity, and methods thereof
WO2018156401A1 (en) * 2017-02-24 2018-08-30 Indiana University Research And Technology Corporation Methods of inhibiting serum glucocorticoid induced kinase 1 (sgk1) as a treatment for salt and water balance diseases
BR112021023562A2 (pt) 2019-06-14 2022-01-04 Janssen Pharmaceutica Nv Carbamatos de pirazina e seus usos como moduladores do receptor de glun2b
KR20220024512A (ko) 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. 치환된 헤테로방향족 피라졸로-피리딘 및 GluN2B 수용체 조절제로서의 이의 용도
AU2020292994A1 (en) * 2019-06-14 2022-01-06 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators
EP3983074A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Pyridine carbamates and their use as glun2b receptor modulators
WO2020249792A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
WO2024015055A1 (en) * 2022-07-13 2024-01-18 Thryv Therapeutics Inc. Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 and treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6690240B2 (en) 2002-01-10 2004-02-10 Cirrus Logic, Inc. Low-jitter loop filter for a phase-locked loop system
AU2004274403A1 (en) 2003-09-03 2005-03-31 Aventis Pharmaceuticals Inc. 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds
DE102004059781A1 (de) 2004-12-10 2006-06-22 Sanofi-Aventis Deutschland Gmbh Verwendung der Serum-/Glucocorticoid regulierten Kinase
DE102005015255A1 (de) 2005-04-04 2006-10-05 Merck Patent Gmbh Acylhydrazide
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102007002717A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate
AU2011377409B2 (en) 2011-09-19 2017-05-25 Sanofi N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals
US20130072493A1 (en) 2011-09-19 2013-03-21 Sanofi N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS

Also Published As

Publication number Publication date
BR112014006207A2 (pt) 2017-04-11
MY179987A (en) 2020-11-19
CY1117006T1 (el) 2017-04-05
EA024295B1 (ru) 2016-09-30
HUE026072T2 (en) 2016-05-30
EA201490662A1 (ru) 2014-07-30
ES2552836T3 (es) 2015-12-02
PT2570415E (pt) 2015-11-23
SI2570415T1 (sl) 2015-12-31
HRP20151183T1 (hr) 2015-12-04
EP2758399A1 (en) 2014-07-30
EP2570415B1 (en) 2015-08-26
EP2570415A8 (en) 2013-05-22
US20140357640A1 (en) 2014-12-04
TW201329079A (zh) 2013-07-16
PL2570415T3 (pl) 2016-01-29
WO2013041502A1 (en) 2013-03-28
DK2570415T3 (en) 2015-11-23
EP2758399B1 (en) 2017-11-15
US9174993B2 (en) 2015-11-03
MX342869B (es) 2016-10-17
EP2570415A1 (en) 2013-03-20
ES2659551T3 (es) 2018-03-16
AR087907A1 (es) 2014-04-23
TWI577679B (zh) 2017-04-11

Similar Documents

Publication Publication Date Title
MX363658B (es) N-(4-(azaindazol-6-il)-fenil)-sulfonamidas y su uso como productos farmacéuticos.
MX342869B (es) N-[4-(1h-pirazolo[3,4-b]pirazin-6-il)-fenil]-sulfonamidas y su uso como productos farmaceuticos.
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
MX2021013941A (es) Inhibidores del inflamasoma nlrp3.
WO2008074997A8 (en) Pyridine benzamides and pyrazine benzamides used as pkd inhibitors
MX342873B (es) Derivados de pirazolo-quinazolina sustituidos como inhibidores de cinasa.
MX344479B (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de cinasa janus (jak).
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
NZ703124A (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
IN2014KN00929A (es)
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
MY160305A (en) Imidazo [1,2-a] pyrazine derivatives and their use for the prevention or treatment of neurological,psychiatric and metabolic disorders and diseases
MY147647A (en) Imidazo [1,2-a] pyridine derivatives : preparation and pharmaceutical applications
EA201391752A1 (ru) Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2
MX2014003408A (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1).
EA020703B9 (ru) Пиразолохиназолины
EA201291098A1 (ru) Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ
UA102828C2 (en) Amino triazoles as p13k inhibitors
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
WO2013004995A8 (en) Pyrimidinone compounds and their use
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
MX2013014194A (es) 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
MX341577B (es) Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero.

Legal Events

Date Code Title Description
FG Grant or registration